pillbase.ru

Ultomiris

Active substance: ravulizumab

ravulizumab

Centralised EU authorisationActive

Marketing holder: Alexion Europe SAS

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 3
  • Ultomiris
    SOLUTION, CONCENTRATE · RAVULIZUMAB 300 mg/30mL
    25682-022
    Alexion Pharmaceuticals Inc.
  • Ultomiris
    SOLUTION, CONCENTRATE · RAVULIZUMAB 300 mg/3mL
    25682-025
    Alexion Pharmaceuticals Inc.
  • Ultomiris
    SOLUTION, CONCENTRATE · RAVULIZUMAB 1100 mg/11mL
    25682-028
    Alexion Pharmaceuticals Inc.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a12091-7627-7863-96e6-d1591112c0ed,01a12091-7629-74e8-9ae1-fc8d78490cf4,01a12091-762b-71e8-9c7f-6503eb3f4429;count=3 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/004954
Registration status
Active
ATC code
L04AA43
Sources
  • product · EMA · EMEA/H/C/004954 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/004954 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/004954 · Verified 2026-10-09